

SN5-27 and three variants thereof, (9Gln-SN5-27, I5Asn-SN5-21 and 9Gln-I5Asn-SN5-27). 15-Lys-SN has also been described in the art (Gardener et al, 1979) . Haffer et al (1991) describe eight secretin variants with reduced peptide bonds (the -CONH- bond being replaced by -CH2-HN-) between one of the eight N-terminal peptide bonds. Robberecht et al (1988) describe secretin fragments 2-27, 3-27, 5-27 and 7-27 and observed activity for secreting receptors. Konig et al (1986) exchanged the N-terminal 5 amino acids of a secretin for the N-terminal pentapeptide sequence of human somatotropin releasing factor to provide I-Tyr-2,4-diAla-5-Ile-SN, which showed secretin activity. Other active variants made were 3-L-Cystic acid-SN, 6-D-Phe-SN, 5-Allo-Thr-SN, and I-Cys-6-Cys-SN.--

Insert the attached Sequence Listing after the claims pages.

#### **REMARKS**

Reconsideration is requested.

The specification has been amended to include the attached Sequence Listing in response to the Notice to Comply dated October 22, 2001. The attached paper and computer-readable copies of the Sequence Listing are the same.

No new matter has been added.

An early and favorable Action on the merits is requested.